Review ArticleReview Article
Open Access

A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes

Khalid Z. Alshali and Abdullah M. Karawagh
Saudi Medical Journal August 2016, 37 (8) 834-842; DOI: https://doi.org/10.15537/smj.2016.8.15800

References

  1. ↵
    1. Holst JJ,
    2. Vilsbøll T,
    3. Deacon CF
    (2009) The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 297:127–136.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Drucker DJ,
    2. Nauck MA
    (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696–1705.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Baggio LL,
    2. Drucker DJ
    (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131–2157.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Nauck M,
    2. Stöckmann F,
    3. Ebert R,
    4. Creutzfeldt W
    (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46–52.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Zander M,
    2. Madsbad S,
    3. Madsen JL,
    4. Holst JJ
    (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824–830.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. American Diabetes Association. Classification and diagnosis of diabetes. Sec. 2. In: Standards of Medical Care in Diabetes-2016
    (2016) Diabetes Care 39(Suppl 1):S13–S22.
    OpenUrlFREE Full Text
  7. ↵
    1. American Diabetes Association. Glycemic targets. Sec. 5. In Standards of Medical Care in Diabetes-2016
    (2016) Diabetes Care 39(Suppl 1):S33–S40.
    OpenUrl
  8. ↵
    1. International Diabetes Federation Guideline Development Group
    (2014) Global guideline for type 2 diabetes. Diabetes Res Clin Pract 104:1–52.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Al-Arouj M,
    2. Al-Magd MA,
    3. Bougerra R,
    4. Buse JB,
    5. Edelman SV,
    6. Fahmy M,
    7. et al.
    (2007) Recommendations for management of hyperglycaemia in Arab countries. Based on the consensus statement form the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Clin Diabetes (Middle East Edition) 6:118–124.
    OpenUrl
  10. ↵
    1. Inzucchi SE,
    2. Bergenstal RM,
    3. Buse JB,
    4. Diamant M,
    5. Ferrannini E,
    6. Nauck M,
    7. et al.
    (2015) Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38:140–149.
    OpenUrlFREE Full Text
  11. ↵
    1. Handelsman Y,
    2. Bloomgarden ZT,
    3. Grunberger G,
    4. Umpierrez G,
    5. Zimmerman RS,
    6. Bailey TS,
    7. et al.
    (2015) American Association of Clinical Endocrinologists and American College Of Endocrinology-Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan- 2015. Endocr Pract 21(Suppl 1):1–87.
    OpenUrlPubMed
  12. ↵
    1. Rodbard HW,
    2. Jellinger PS,
    3. Davidson JA,
    4. Einhorn D,
    5. Garber AJ,
    6. Grunberger G,
    7. et al.
    (2009) Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycaemic control. Endocr Pract 15:768–770.
    OpenUrlCrossRef
  13. ↵
    1. American Diabetes Association
    (2016) Approaches to glycemic treatment. In Standards of Medical Care in Diabetes-2016. Diabetes Care 39(Suppl 1):S52–S59.
    OpenUrlFREE Full Text
  14. ↵
    1. Nisal K,
    2. Kela R,
    3. Khunti K,
    4. Davies MJ
    (2012) Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus. BMC Med 10:152.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Nauck M
    (2016) Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab 18:203–216.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Pratley RE,
    2. Gilbert M
    (2008) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Rev Diabet Stud 5:73–94.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Byetta®(exenatide bid) [package insert]
    AstraZeneca Pharmaceuticals LP, Available from URL: http://www.azpicentral.com/byetta/pi_byetta.pdf. Updated 2014. Accessed 2015 March 19.
  18. ↵
    1. Victoza®(liraglutide qd)
    European Medical Agency. Summary of Product Characteristics. Novo Nordisk A/S, Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001026/WC500050017.pdf. Updated 2014. Accessed 2015 March 19.
  19. ↵
    1. Chia CW,
    2. Egan JM
    (2008) Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab 93:3703–3716.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Garber A,
    2. Henry R,
    3. Ratner R,
    4. Garcia-Hernandez PA,
    5. Rodriguez-Pattzi H,
    6. Olvera-Alvarez I,
    7. et al.
    (2009) Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week, phase III, double-blind, parallel- treatment trial. Lancet 373:473–481.
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    1. Seino Y,
    2. Rasmussen MF,
    3. Nishida T,
    4. Kaku K
    (2010) Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin 26:1013–1022.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Moretto TJ,
    2. Milton DR,
    3. Ridge TD,
    4. Macconell LA,
    5. Okerson T,
    6. Wolka AM,
    7. et al.
    (2008) Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 30:1448–1460.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Bydureon™(exenatide extended-release for injectable suspension) [prescribing information]
    AstraZeneca Pharmaceuticals LP, Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022200s000lbl.pdf. Updated 2015. Accessed 2016 June 03.
    1. Tanzeum®(albiglutide) [package insert]
    GlaxoSmithKline LLC, Available from URL: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Tanzeum/pdf/TANZEUM-PI-MG-IFU-COMBINED.PDF. Updated 2014. Accessed 2016 June 03.
    1. Trulicity®(dulaglutide) [prescribing information]
    Eli Lilly and Company, Available from URL: http://pi.lilly.com/us/trulicity-uspi.pdf. Updated 2014. Accessed 2016 June 03.
  26. ↵
    1. Lyxumia®(lixisenatide)
    European Medical Agency. Summary of product characteristics, Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002445/WC500140401.pdf. Updated 2013. Accessed 2016 June 03.
  27. ↵
    1. Ahrén B
    (2007) DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab 21:517–533.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Januvia®(sitagliptin qd) [package insert]
    Merck & Co Inc, Available from URL: http://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdf. Updated 2015. Accessed 2016 June 03.
  29. ↵
    1. Hermansen K,
    2. Kipnes M,
    3. Luo E,
    4. Fanurik D,
    5. Khatami H,
    6. Stein P,
    7. et al.
    (2007) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 9:733–745.
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    1. Harashima SI,
    2. Ogura M,
    3. Tanaka D,
    4. Fukushima T,
    5. Wang Y,
    6. Koizumi T,
    7. et al.
    (2012) Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycemic control and insulin secretion capacity in type 2 diabetes. Int J Clin Pract 66:465–476.
    OpenUrlPubMed
  31. ↵
    1. Onglyza®(saxagliptin) [package insert]
    Bristol-Myers Squibb Company and AstraZeneca Pharmaceuticals LP, Available from URL: http://www.azpicentral.com/onglyza/pi_onglyza.pdf. Updated 2016. Accessed 2016 June 03.
    1. Tradjenta®(linagliptin) [package insert]
    Boehringer Ingelheim, Available from URL: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Tradjenta/Tradjenta.pdf. Updated 2016. Accessed 2016 June 03.
    1. Galvus®(vildagliptin)
    European Medical Agency. Summary of Product Characteristics, Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000771/WC500020327.pdf. Updated 2016. Accessed 2016 June 03.
  34. ↵
    1. Nesina®(alogliptin) [package insert]
    Takeda Pharmaceuticals America Inc, Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022271s000lbl.pdf. Updated 2013. Accessed 2016 June 03.
  35. ↵
    1. Buse JB,
    2. Rosenstock J,
    3. Sesti G,
    4. Schmidt WE,
    5. Montanya E,
    6. Brett JH,
    7. et al.
    (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374:39–47.
    OpenUrlCrossRefPubMedWeb of Science
  36. ↵
    1. Buse JB,
    2. Sesti G,
    3. Schmidt WE,
    4. Montanya E,
    5. Chang CT,
    6. Xu Y,
    7. et al.
    (2010) Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 33:1300–1303.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Pratley RE,
    2. Nauck M,
    3. Bailey T,
    4. Montanya E,
    5. Cuddihy R,
    6. Filetti S,
    7. et al.
    (2010) Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 375:1447–1456.
    OpenUrlCrossRefPubMedWeb of Science
  38. ↵
    1. Pratley R,
    2. Nauck M,
    3. Bailey T,
    4. Montanya E,
    5. Cuddihy R,
    6. Filetti S,
    7. et al.
    (2011) One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 65:397–407.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Pratley RE,
    2. Nauck MA,
    3. Bailey T,
    4. Montanya E,
    5. Filetti S,
    6. Garber AJ,
    7. et al.
    (2012) Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care 35:1986–1993.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    1. King AB,
    2. Montanya E,
    3. Pratley RE,
    4. Blonde L,
    5. Svendsen CB,
    6. Donsmark M,
    7. et al.
    (2013) Liraglutide achieves A1c targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1c<8.0%. Endocr Pract 19:64–72.
    OpenUrlPubMed
  41. ↵
    1. Lee WC,
    2. Dekoven M,
    3. Bouchard J,
    4. Massoudi M,
    5. Langer J
    (2014) Improved real-world glycaemic outcomes with liraglutide versus other incretin-based therapies in type 2 diabetes. Diabetes Obes Metab 16:819–826.
    OpenUrl
  42. ↵
    1. Li Q,
    2. Chitnis A,
    3. Hammer M,
    4. Langer J
    (2014) Real-world clinical and economic outcomes of liraglutide versus sitagliptin in patients with type 2 diabetes mellitus in the United States. Diabetes Ther 5:579–590.
    OpenUrlCrossRefPubMed
  43. ↵
    1. Scheen AJ
    (2014) Which incretin-based therapy for type 2 diabetes? Lancet 384:1325–1327.
    OpenUrlCrossRefPubMed
  44. ↵
    1. Cobble M
    (2012) Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus. Diabetol Metab Syndr 4:8.
    OpenUrlCrossRefPubMed
  45. ↵
    1. Trujillo JM,
    2. Nuffer W,
    3. Ellis SL
    (2015) GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab 6:19–28.
    OpenUrlCrossRefPubMed
  46. ↵
    1. Madsbad S
    (2016) Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab 18:317–332.
    OpenUrlCrossRefPubMed
  47. ↵
    1. Buse JB,
    2. Nauck M,
    3. Forst T,
    4. Sheu WH,
    5. Shenouda SK,
    6. Heilmann CR,
    7. et al.
    (2013) Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 381:117–124.
    OpenUrlCrossRefPubMedWeb of Science
  48. ↵
    1. Gupta V,
    2. Kalra S
    (2011) Choosing a gliptin. Indian J Endocrinol Metab 15:298–308.
    OpenUrlPubMed
  49. ↵
    1. U.S. Food and Drug Administration
    FDA drug safety communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain, Available from URL: http://www.fda.gov/Drugs/DrugSafety/ucm459579.htm. Updated 2015. Accessed 2016 June 03.
  50. ↵
    1. George RE,
    2. Joseph S
    (2014) A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy. Saudi Pharm J 22:403–410.
    OpenUrl
  51. ↵
    1. Buse JB,
    2. Henry RR,
    3. Han J,
    4. Kim DD,
    5. Fineman MS,
    6. Baron AD,
    7. et al.
    (2004) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27:2628–2635.
    OpenUrlAbstract/FREE Full Text
    1. Kendall DM,
    2. Riddle MC,
    3. Rosenstock J,
    4. Zhuang D,
    5. Kim DD,
    6. Fineman MS,
    7. et al.
    (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28:1083–1091.
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. Zinman B,
    2. Hoogwerf BJ,
    3. Durán García S,
    4. Milton DR,
    5. Giaconia JM,
    6. Kim DD,
    7. et al.
    (2007) The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomised trial. Ann Intern Med 146:477–485.
    OpenUrlCrossRefPubMedWeb of Science
    1. Derosa G,
    2. Franzetti IG,
    3. Querci F,
    4. Carbone A,
    5. Ciccarelli L,
    6. Piccinni MN,
    7. et al.
    (2012) Exenatide plus metformin compared with metformin alone on ß-cell function in patients with type 2 diabetes. Diabet Med 29:1515–1523.
    OpenUrlCrossRefPubMed
    1. Nauck M,
    2. Frid A,
    3. Hermansen K,
    4. Shah NS,
    5. Tankova T,
    6. Mitha IH,
    7. et al.
    (2009) Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 32:84–90.
    OpenUrlAbstract/FREE Full Text
    1. Russell-Jones D,
    2. Vaag A,
    3. Schmitz O,
    4. Sethi BK,
    5. Lalic N,
    6. Antic S,
    7. et al.
    (2009) Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 52:2046–2055.
    OpenUrlCrossRefPubMedWeb of Science
    1. Seino Y,
    2. Rasmussen MF,
    3. Nishida T,
    4. Kaku K
    (2011) Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial. J Diabetes Investig 2:280–286.
    OpenUrl
  58. ↵
    1. Zinman B,
    2. Gerich J,
    3. Buse JB,
    4. Lewin A,
    5. Schwartz S,
    6. Raskin P,
    7. et al.,
    8. LEAD-4 Study Investigators
    (2009) Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 32:1224–1230.
    OpenUrlAbstract/FREE Full Text
  59. ↵
    1. Fakhoury WK,
    2. Lereun C,
    3. Wright D
    (2010) A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 86:44–57.
    OpenUrlCrossRefPubMedWeb of Science
  60. ↵
    1. Evans M,
    2. McEwan P,
    3. O’Shea R,
    4. George L
    (2013) A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice. Diabetes Ther 4:27–40.
    OpenUrl
  61. ↵
    1. Esposito K,
    2. Mosca C,
    3. Brancario C,
    4. Chiodini P,
    5. Ceriello A,
    6. Giugliano D
    (2011) GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Curr Med Res Opin 27:1519–1528.
    OpenUrlCrossRefPubMed
  62. ↵
    1. International Diabetes Federation
    (2015) IDF Diabetes (International Diabetes Federation, Brussels (Belgium)), 7th ed.
    1. Al-Elq AH
    (2009) Current practice in the management of patients with type 2 diabetes mellitus in Saudi Arabia. Saudi Med J 30:1551–1556.
    OpenUrlPubMed
  64. ↵
    1. Al-Maatouq M,
    2. Al-Arouj M,
    3. Assaad SH,
    4. Assaad SN,
    5. Azar ST,
    6. Hassoun AA,
    7. et al.
    (2010) Optimising the medical management of hyperglycaemia in type 2 diabetes in the Middle East: pivotal role of metformin. Int J Clin Pract 64:149–159.
    OpenUrlPubMed
    1. Al-Akour NA,
    2. Khader YS,
    3. Alaoui AM
    (2011) Glycemic control and its determinants among patients with type 2 diabetes mellitus attending a teaching hospital. J Diabetes Metab 2:129.
    OpenUrl
  66. ↵
    1. Khattab M,
    2. Khader YS,
    3. Al-Khawaldeh A,
    4. Ajlouni K
    (2010) Factors associated with poor glycemic control among patients with type 2 diabetes. J Diabetes Complications 24:84–89.
    OpenUrlCrossRefPubMedWeb of Science
  67. ↵
    1. Ghuman NK,
    2. Saadah LM,
    3. Al Najjar MS,
    4. Shaheen DY,
    5. Am SI,
    6. Al Ali MM
    (2015) Effectiveness of liraglutide in type II diabetes mellitus management: experience in Emirati patients. Clin Med Insights Endocrinol Diabetes 8:67–72.
    OpenUrl
  68. ↵
    1. Khalil AB,
    2. Beshyah SA,
    3. Benbarka MM,
    4. DaBell J,
    5. Bernsen R
    (2010) The effect of sitagliptin therapy in suboptimally controlled metformin-treated type 2 diabetes patients: a Middle Eastern experience. Int J Diabetes & Metab 18:55–58.
    OpenUrl
  69. ↵
    1. Saab C,
    2. Al-Saber FA,
    3. Haddad J,
    4. Jallo MK,
    5. Steitieh H,
    6. Bader G,
    7. et al.
    (2015) Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study. Vasc Health Risk Manag 11:149–155.
    OpenUrl
  70. ↵
    1. Brady EM,
    2. Davies MJ,
    3. Gray LJ,
    4. Saeed MA,
    5. Smith D,
    6. Hanif W,
    7. et al.
    (2014) A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial. Diabetes Obes Metab 16:527–536.
    OpenUrlPubMed
    1. Khalifa AA,
    2. El Rashid AO,
    3. Bashier AMK
    (2015) 2015 Safety and efficacy of liraglutide as an add-on therapy to pre-existing anti-diabetic regimens during Ramadan, A Prospective Observational Trial. J Diabetes Metab 6:590.
    OpenUrl
  72. ↵
    1. Al Sifri S,
    2. Basiounny A,
    3. Echtay A,
    4. Al Omari M,
    5. Harman-Boehm I,
    6. Kaddaha G,
    7. et al.
    (2011) The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. Int J Clin Pract 65:1132–1140.
    OpenUrlCrossRefPubMed
  73. ↵
    1. Schmidt WE,
    2. Christiansen JS,
    3. Hammer M,
    4. Zychma MJ,
    5. Buse JB
    (2011) Patient-reported outcomes are superior in patients with type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study. Diabet Med 28:715–723.
    OpenUrlCrossRefPubMed
  74. ↵
    1. Davies M,
    2. Pratley R,
    3. Hammer M,
    4. Thomsen AB,
    5. Cuddihy R
    (2011) Liraglutide improves treatment satisfaction in people with type 2 diabetes compared with sitagliptin, each as an add on to metformin. Diabet Med 28:333–337.
    OpenUrlPubMed
  75. ↵
    1. DeKoven M,
    2. Lee WC,
    3. Bouchard J,
    4. Massoudi M,
    5. Langer J
    (2014) Real-world cost-effectiveness: lower cost of treating patients to glycemic goal with liraglutide versus exenatide. Adv Ther 31:202–216.
    OpenUrlCrossRefPubMed
    1. Valentine WJ,
    2. Palmer AJ,
    3. Lammert M,
    4. Langer J,
    5. Brändle M
    (2011) Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents. Clin Ther 33:1698–1712.
    OpenUrlPubMed
  77. ↵
    1. Lee WC,
    2. Samyshkin Y,
    3. Langer J,
    4. Palmer JL
    (2012) Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis. J Med Econ 15(Suppl 2):28–37.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section